Systematic Financial Management LP increased its stake in shares of Icon Plc (NASDAQ:ICLR) by 8.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,042 shares of the medical research company’s stock after buying an additional 755 shares during the quarter. Systematic Financial Management LP’s holdings in Icon were worth $1,372,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in ICLR. Pendal Group Ltd lifted its position in Icon by 48,582.8% during the fourth quarter. Pendal Group Ltd now owns 1,405,471 shares of the medical research company’s stock worth $181,601,000 after buying an additional 1,402,584 shares in the last quarter. Norges Bank acquired a new stake in Icon during the fourth quarter worth $84,127,000. WCM Investment Management LLC increased its stake in Icon by 5.4% during the fourth quarter. WCM Investment Management LLC now owns 5,272,086 shares of the medical research company’s stock worth $681,207,000 after acquiring an additional 271,375 shares during the last quarter. State of Tennessee Treasury Department acquired a new stake in Icon during the fourth quarter worth $23,301,000. Finally, American Century Companies Inc. acquired a new stake in Icon during the fourth quarter worth $22,158,000. Hedge funds and other institutional investors own 87.65% of the company’s stock.
Shares of NASDAQ ICLR traded down $0.05 during trading on Friday, reaching $140.97. The stock had a trading volume of 3,208 shares, compared to its average volume of 316,055. Icon Plc has a fifty-two week low of $118.10 and a fifty-two week high of $155.33. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $7.48 billion, a PE ratio of 22.23, a PEG ratio of 1.91 and a beta of 0.62.
Several equities research analysts have issued reports on the company. SunTrust Banks reissued a “buy” rating and set a $161.00 target price on shares of Icon in a research note on Monday, February 25th. BidaskClub raised Icon from a “sell” rating to a “hold” rating in a research note on Thursday, April 4th. Barclays raised their target price on Icon from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Monday, March 18th. ValuEngine raised Icon from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Finally, Zacks Investment Research raised Icon from a “hold” rating to a “buy” rating and set a $146.00 target price for the company in a research note on Wednesday, April 24th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $153.20.
WARNING: This piece was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4344573/systematic-financial-management-lp-has-1-37-million-position-in-icon-plc-iclr.html.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Story: What is the Rule of 72?
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.